30
Participants
Start Date
March 31, 2014
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
FMP2.1/AS01B
50 µg FMP2.1 in 0.5 mL of the adjuvant AS01B (containing 50 mcg MPL + 50 mcg QS21) is administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton, Southampton
NIHR Wellcome Trust Clinical Research Facility (NIHR WTCRF), Hammersmith Hospital, London
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford
The PATH Malaria Vaccine Initiative (MVI)
OTHER
National Institute for Health Research, United Kingdom
OTHER_GOV
University of Oxford
OTHER